Independent Medical Education Request for Proposals: Improving Shared Decision Making in Hemophilia Visiting Professorship Program 2026, Semester 2
Pfizer Inc. funds a 2026 visiting professorship program to advance shared decision making and education on new therapies in hemophilia care.
Funder: Pfizer Inc.
Due Dates: September 17, 2026: Deadline for Applications
Funding Amounts: Up to $6,000 per grant (logistics only); approx. 9 sites funded; Visiting Professor expenses covered separately
Summary: Supports organizations hosting hemophilia-focused Visiting Professorships to improve shared decision making and education on emerging therapies.
Key Information: Applications only accepted between September 3–17, 2026 due to system transition.
Description
Pfizer Inc., in partnership with the Hemostasis & Thrombosis Research Society (HTRS), invites applications for the Independent Medical Education Visiting Professorship Program focused on improving shared decision making in hemophilia care. This grant supports organizations wishing to host a tailored, up-to-two-day medical education program led by a distinguished Visiting Professor with expertise in hemophilia, addressing unmet educational needs related to shared decision making and new therapeutic options. The initiative aims to advance clinician and care team knowledge, facilitate multidisciplinary collaboration, and ultimately enhance patient outcomes in hemophilia.
